0001209191-18-011662.txt : 20180220
0001209191-18-011662.hdr.sgml : 20180220
20180220202207
ACCESSION NUMBER: 0001209191-18-011662
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180215
FILED AS OF DATE: 20180220
DATE AS OF CHANGE: 20180220
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Ciechanover Isaac E.
CENTRAL INDEX KEY: 0001612096
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36548
FILM NUMBER: 18626717
MAIL ADDRESS:
STREET 1: C/O ATARA BIOTHERAPEUTICS, INC.
STREET 2: 3260 BAYSHORE BOULEVARD
CITY: BRISBANE
STATE: CA
ZIP: 94005
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Atara Biotherapeutics, Inc.
CENTRAL INDEX KEY: 0001604464
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 460920988
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 611 GATEWAY BLVD
STREET 2: SUITE 900
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: 650-278-8930
MAIL ADDRESS:
STREET 1: 611 GATEWAY BLVD
STREET 2: SUITE 900
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2018-02-15
0
0001604464
Atara Biotherapeutics, Inc.
ATRA
0001612096
Ciechanover Isaac E.
611 GATEWAY BOULEVARD
SUITE 900
SOUTH SAN FRANCISCO
CA
94080
1
1
0
0
Chief Executive Officer
Common Stock
2018-02-15
4
S
0
2500
45.58
D
260378
I
See footnote
Common Stock
2018-02-15
4
S
0
2433
46.71
D
257945
I
See footnote
Common Stock
2018-02-15
4
S
0
4767
47.56
D
253178
I
See footnote
Common Stock
2018-02-15
4
S
0
300
48.25
D
252878
I
See footnote
Common Stock
2018-02-16
4
S
0
3000
45.44
D
249878
I
See footnote
Common Stock
2018-02-16
4
S
0
1600
46.55
D
248278
I
See footnote
Common Stock
2018-02-16
4
S
0
5100
47.91
D
243178
I
See footnote
Common Stock
2018-02-16
4
S
0
300
48.43
D
242878
I
See footnote
Common Stock
2018-02-15
4
M
0
3938
0.00
A
812613
D
Restricted Stock Units
2018-02-15
4
M
0
3938
0.00
D
Common Stock
3938
0
D
Transaction pursuant to Rule 10b5-1 Plan adopted May 18, 2017.
The price in Column 4 is a weighted average sale price. The prices actually received ranged from $45.00 to $46.00. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee.
The price in Column 4 is a weighted average sale price. The prices actually received ranged from $46.10 to $47.10. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
The price in Column 4 is a weighted average sale price. The prices actually received ranged from $47.15 to $48.15. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
The price in Column 4 is a weighted average sale price. The prices actually received ranged from $46.15 to $47.10. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
The price in Column 4 is a weighted average sale price. The prices actually received ranged from $47.25 to $48.20. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
The price in Column 4 is a weighted average sale price. The prices actually received ranged from $48.30 to $48.55. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
Shares issued upon settlement of vested restricted stock units ("RSUs").
Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock or a cash settlement.
Fully vested.
The earlier of (i) January 10, 2021 or (ii) the recipient's termination date.
/s/ David Tucker, Attorney-in-Fact for Isaac E. Ciechanover
2018-02-20